Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC)

被引：1
|
作者：
Jiang, Di Maria
Sim, Hao-Wen
Siu, Lillian L.
Shapiro, Jeremy David
Liu, Geoffrey
Price, Timothy Jay
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.699
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
699
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).
    Jiang, Di Maria
    Sim, Hao-Wen
    Siu, Lillian L.
    Shapiro, Jeremy David
    Liu, Geoffrey
    Price, Timothy Jay
    Jonker, Derek J.
    Karapetis, Christos Stelios
    Strickland, Andrew
    Zhang, Wenjiang
    Jeffery, Mark
    Tu, Dongsheng
    Ng, Siobhan
    Sabesan, Sabe S.
    Shannon, Jenny
    Townsend, Amanda Rose
    Morgen, Eric
    Xu, Wei
    O'Callaghan, Christopher J.
    Chen, Eric Xueyu
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Successful desensitization with cetuximab (CET) after hypersensitivity reaction (HSR) to panitumumab (PAN) and CET in patients (pts) with metastatic colorectal cancer (mCRC)
    Shah, M. M.
    Hotchkiss, S.
    Shanley, J.
    Davies, M. J.
    Ferencz, T. M.
    Syrigos, K. I.
    Syrigos, K.
    Saif, M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Immune signatures to affect overall survival (OS) and response to bevacizumab (Bev) or cetuximab (Cet) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance).
    Innocenti, Federico
    Yazdani, Akram
    Qu, Xueping
    Ou, Fang-Shu
    Van Buren, Scott
    Kabbarah, Omar
    Blanke, Charles David
    Venook, Alan P.
    Lenz, Heinz-Josef
    Vincent, Benjamin Garrett
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Molecular characterization of metastatic colorectal cancer (mCRC) in patients (pts) treated with cetuximab and pembrolizumab.
    Fountzilas, Christos
    Rosario, Spencer
    Withers, Henry G.
    Mukherjee, Sarbajit
    Bajor, David L.
    Saltzman, Joel N.
    Wang, Chong
    Attwood, Kristopher
    Knudsen, Erik S.
    Witkiewicz, Agnieszka K.
    Iyer, Renuka V.
    Boland, Patrick M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 178 - 178
  • [5] Institutional experiences with panitumumab monotherapy in metastatic colorectal cancer (mCRC) patients (pts) intolerant to cetuximab
    Langerak, A. D.
    Mitchell, E.
    Cheema, P.
    River, G. L.
    Shing, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Successful desensitisation with cetuximab (CET) after hypersensitivity reaction (HSR) to panitumumab (PAN) and CET in patients with metastatic colorectal cancer (mCRC)
    Syrigou, E.
    Shah, M.
    Kotteas, E.
    Alamara, C.
    Saif, M.
    Syrigos, K.
    ALLERGY, 2008, 63 : 375 - 375
  • [7] Safety and convenience of cetuximab (cet) and irinotecan (iri) both given every two weeks in metastatic colorectal cancer (mcrc) patients (pts).: Pereliminary report
    Colina, P.
    Antonelli, G.
    D'Angelo, A.
    Giamo, V
    Priolo, D.
    Ferrau, F.
    ANNALS OF ONCOLOGY, 2007, 18 : 188 - 188
  • [8] Safety and convenience of cetuximab (cet) and irinotecan (iri) both given every two weeks in metastatic colorectal cancer (mcrc) patients (pts).: Preliminary report
    Colina, P.
    Antonelli, G.
    D'Angelo, A.
    Giamo, V
    Priolo, D.
    Ferrau, F.
    ANNALS OF ONCOLOGY, 2007, 18 : 188 - 188
  • [9] Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI ± bevacizumab (BV) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC)
    Baron, A. D.
    O'Bryant, C. L.
    Choi, Y.
    Ashkenazi, A.
    Royer-Joo, S.
    Portera, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Liver and/or lung metastasectomy after cetuximab or bevacizumab plus FOLFIRI chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC).
    Kim, Sang-A
    Kim, Ji-Won
    Suh, Koung Jin
    Kim, Jin Won
    Oh, Heung-Kwon
    Cho, Jai Young
    Kim, Duck-Woo
    Lee, Keun-Wook
    Cho, Sukki
    Kim, Jee Hyun
    Kim, Kwhanmien
    Kang, Sung-Bum
    Jheon, Sanghoon
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345